BioHarvest Sciences (NASDAQ:BHST) Trading Down 1.1% – Time to Sell?

BioHarvest Sciences Inc. (NASDAQ:BHST) fell 1.1% during mid-day trading on Thursday . The company traded as low as $4.65 and last traded at $4.65. 18,552 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 37,636 shares. The stock had previously closed at $4.70.

Analyst Ratings Changes

A number of research analysts recently weighed in on BHST shares. Wall Street Zen upgraded shares of BioHarvest Sciences to a “hold” rating in a research note on Saturday, October 18th. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, BioHarvest Sciences has an average rating of “Hold” and a consensus target price of $14.50.

BioHarvest Sciences Trading Down 1.1%

The company has a debt-to-equity ratio of 0.30, a current ratio of 1.35 and a quick ratio of 1.02. The stock has a market cap of $76.35 million, a P/E ratio of -6.84 and a beta of 1.12. The stock’s 50-day moving average is $5.38 and its two-hundred day moving average is $7.63.

BioHarvest Sciences (NASDAQ:BHST) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). The business had revenue of $9.07 million during the quarter, compared to the consensus estimate of $9.11 million. BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%. Equities research analysts anticipate that BioHarvest Sciences Inc. will post -0.8 EPS for the current year.

Institutional Trading of BioHarvest Sciences

A hedge fund recently raised its stake in BioHarvest Sciences stock. True North Advisors LLC grew its position in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) by 676.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 168,013 shares of the company’s stock after acquiring an additional 146,365 shares during the quarter. True North Advisors LLC owned about 1.02% of BioHarvest Sciences worth $1,581,000 at the end of the most recent reporting period.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.